SANTANDREA, GIACOMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.080
AS - Asia 1.723
EU - Europa 918
SA - Sud America 228
AF - Africa 88
Continente sconosciuto - Info sul continente non disponibili 40
OC - Oceania 11
Totale 5.088
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.958
CN - Cina 510
SG - Singapore 428
IT - Italia 385
HK - Hong Kong 189
BR - Brasile 171
VN - Vietnam 171
GB - Regno Unito 116
BD - Bangladesh 88
KR - Corea 82
DE - Germania 76
RU - Federazione Russa 68
SE - Svezia 56
CA - Canada 53
IN - India 52
FR - Francia 44
ID - Indonesia 39
EG - Egitto 34
FI - Finlandia 32
NL - Olanda 29
MX - Messico 27
AR - Argentina 26
PK - Pakistan 25
IQ - Iraq 24
IR - Iran 23
ZA - Sudafrica 19
PL - Polonia 18
TR - Turchia 14
LT - Lituania 13
EC - Ecuador 12
ES - Italia 12
UA - Ucraina 12
AU - Australia 11
JP - Giappone 11
PH - Filippine 11
CO - Colombia 10
IL - Israele 10
AE - Emirati Arabi Uniti 7
AT - Austria 7
BE - Belgio 7
CH - Svizzera 7
HN - Honduras 7
NG - Nigeria 7
SA - Arabia Saudita 7
CW - ???statistics.table.value.countryCode.CW??? 6
IE - Irlanda 6
MA - Marocco 6
MY - Malesia 6
CR - Costa Rica 5
DZ - Algeria 5
JM - Giamaica 5
JO - Giordania 5
PT - Portogallo 5
RO - Romania 5
BG - Bulgaria 4
GP - Guadalupe 4
GT - Guatemala 4
PY - Paraguay 4
RS - Serbia 4
TT - Trinidad e Tobago 4
UZ - Uzbekistan 4
AM - Armenia 3
ET - Etiopia 3
PA - Panama 3
SN - Senegal 3
SV - El Salvador 3
BF - Burkina Faso 2
CI - Costa d'Avorio 2
GD - Grenada 2
GR - Grecia 2
HR - Croazia 2
KE - Kenya 2
KW - Kuwait 2
KZ - Kazakistan 2
SC - Seychelles 2
TN - Tunisia 2
TW - Taiwan 2
UY - Uruguay 2
AL - Albania 1
AO - Angola 1
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
BZ - Belize 1
CL - Cile 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
NI - Nicaragua 1
OM - Oman 1
PR - Porto Rico 1
Totale 5.051
Salva come PNG Salva come JPEG
Città #
Ashburn 344
Santa Clara 294
Singapore 265
Hefei 227
Hong Kong 177
San Jose 163
Council Bluffs 139
Seoul 69
Ho Chi Minh City 60
Beijing 59
Los Angeles 59
London 58
New York 57
Milan 38
Chandler 35
Rome 31
Chicago 30
Hanoi 29
Buffalo 28
The Dalles 26
Helsinki 25
Cairo 23
Jakarta 23
Shanghai 23
São Paulo 23
Bologna 22
Fairfield 21
Lauterbourg 20
Nyköping 20
Kent 16
Munich 16
Naples 16
Schiffdorf 16
Warsaw 16
Dallas 15
Moscow 15
Orem 15
Johannesburg 14
North Bergen 13
Toronto 13
Seattle 12
Salt Lake City 11
Amsterdam 10
Atlanta 10
Bari 10
Da Nang 10
Denver 10
Florence 10
Mexico City 10
Modena 10
Montreal 10
Nuremberg 10
Turin 10
Houston 9
Islamabad 9
Phoenix 9
Tokyo 9
Brembate di Sopra 8
Guayaquil 8
Miami 8
Rio de Janeiro 8
Wuhan 8
Baghdad 7
Boston 7
Brooklyn 7
Cambridge 7
Catania 7
Haiphong 7
Istanbul 7
Charlotte 6
Dhaka 6
Dublin 6
Giza 6
Manchester 6
Poplar 6
Portsmouth 6
Raleigh 6
Redondo Beach 6
Willemstad 6
Amman 5
Ann Arbor 5
Antwerp 5
Bagno a Ripoli 5
Belo Horizonte 5
Bengaluru 5
Campi Bisenzio 5
Columbus 5
Kolkata 5
Kunming 5
Lagos 5
Lahore 5
Las Vegas 5
Migliarino 5
Newark 5
Parma 5
San Diego 5
Turku 5
Austin 4
Belgrade 4
Boardman 4
Totale 2.973
Salva come PNG Salva come JPEG
Nome #
Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists 607
Spatial Distribution of Immune Cells Drives Resistance to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer 309
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 1: Focus on immunohistochemical results with discussion of pre-analytical and interpretation variables 262
Clinical Review of Mucosal Melanoma: The 11-Year Experience of a Referral Center 259
How can we treat vulvar carcinoma in pregnancy? A systematic review of the literature 246
A prognostic model based on residual cancer burden and tumor-infiltrating lymphocytes on residual disease after neoadjuvant therapy in HER2+ breast cancer 233
What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. part 4: Experimental treatments in pre-clinical studies (cell lines and mouse models) 227
Sinonasal NUT Carcinoma: Delayed Diagnosis Due to the COVID-19 Pandemic and a Review of the Literature 220
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 5: Epigenetic regulation of pd-l1 206
Biomarkers changes after neoadjuvant chemotherapy in breast cancer: A seven-year single institution experience 194
PRAME expression in cellular neurothekeoma: A study of 11 cases 184
Patient derived organoids are an useful tool to investigate Hippo pathway involvement in lung cancer 183
Clinically unquestionable but histologically deceptive melanomas in acral skin grafts: PRAME confirms its role 179
What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. Part 3: PD-L1, intracellular signaling pathways and tumor microenvironment 174
The long non-coding RNA TAZ-AS202 promotes lung cancer progression via regulation of the E2F1 transcription factor and activation of Ephrin signaling 173
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 2: Clinic–pathologic correlations 166
Implementing an organoid platform to assess efficacy of PHD inhibitors as anti-cancer agents 161
Digital spatial profiling for pathologists 159
PHD2 (EGLN1) is a novel therapeutic target in KRAS-mutated lung carcinoma 155
Medullary Thyroid Carcinomas Classified According to the International Medullary Carcinoma Grading System and a Surveillance, Epidemiology, and End Results-Based Metastatic Risk Score: A Correlation With Genetic Profile and Angioinvasion 143
LncRNA TAZ-AS202 promotes lung cancer progression through the regulation of the E2F1 transcription factor 142
A Two-Step Protocol for Isolation and Maintenance of Lung Cancer Primary 3D Cultures 124
Harnessing the hypoxia pathway to set a new therapeutic strategy for KRAS-mutated lung adenocarcinoma 118
Characterization of EGLN1 as a pro-oncogenic factor and pharmacological target in lung cancer 104
null 83
Exploring EGLN1 as a therapeutic target for KRAS mutated lung cancer 77
Totale 5.088
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.038
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.038
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202238 0 0 0 0 2 6 3 8 2 2 8 7
2022/2023129 9 12 6 5 10 14 2 15 12 13 14 17
2023/2024442 17 17 30 40 53 40 61 42 18 48 38 38
2024/20251.233 18 41 45 100 215 175 115 65 147 53 118 141
2025/20262.517 221 157 221 295 332 94 291 113 271 215 209 98
2026/2027690 97 129 135 272 57 0 0 0 0 0 0 0
Totale 5.088